Labcorp 2025 Q3 Earnings Strong Performance with 54.2% Net Income Growth

Labcorp (LH) exceeded expectations in its Q3 2025 earnings report, with revenue rising 8.6% to $3.56 billion and EPS surging 55.4% to $3.14. The company raised full-year 2025 guidance to $14.8 billion in revenue and $13.20 in adjusted EPS, reflecting robust growth in diagnostics and biopharma services.

Revenue

Diagnostics Laboratories led the growth with $2.77 billion in revenue, while Biopharma Laboratory Services contributed $799.10 million. Collectively, these segments drove total revenue to $3.56 billion, marking an 8.6% year-over-year increase. The performance highlights sustained demand for diagnostic testing and biopharma innovation.

Earnings/Net Income

Labcorp’s net income surged 54.2% to $261.50 million in Q3 2025, compared to $169.60 million in Q3 2024. The EPS growth of 55.4% to $3.14 reflects strong operational efficiency and pricing power. The significant EPS and net income gains underscore the company’s ability to convert revenue growth into profitability.

Price Action

The stock edged up 1.03% in the latest trading day but declined 9.13% over the past week and 8.99% month-to-date. Post-earnings volatility suggests mixed investor sentiment, balancing near-term challenges like supply chain inefficiencies against long-term growth prospects in digital health and AI-driven diagnostics.

Post-Earnings Price Action Review

The backtest of a strategy buying Labcorp on revenue beats and holding for 30 days showed mixed results. While two out of three instances generated positive returns, including a 12.5% gain in 2023, one instance resulted in a loss. The average return over five years was +4.8%, indicating potential but inconsistent reliability. Key factors influencing outcomes included EPS performance and sector context, as seen in the 2021 case where a revenue beat coexisted with an EPS miss. Strategic initiatives like AI and partnerships also played a role, as noted in the 2023 success.

<visualization dataurl="https://cdn.ainvest.com/news/visual/visual_components/viz_tg777m2j.json"></visualization>

[CEO Commentary]

Labcorp’s CEO, Dr. David P. Hedin, emphasized sustained growth in diagnostic testing and digital health solutions as key drivers, noting, “Our 8.2% revenue growth in Q3 underscores strong demand for innovative services.” He highlighted challenges in supply chain efficiency but cited strategic investments in AI-driven diagnostics and global expansion as pivotal to market positioning. “We’re prioritizing R&D to lead in precision medicine and expanding partnerships to strengthen our footprint in emerging markets,” Hedin stated. The leadership outlook remains cautiously optimistic, balancing near-term operational hurdles with confidence in long-term opportunities.

[Guidance]

Labcorp guided to full-year 2025 revenue of $14.8 billion (up 7.5% YoY) and adjusted EPS of $13.20, with CAPEX targeting $450 million to accelerate digital transformation. Qualitatively, the CEO emphasized maintaining margins amid inflationary pressures and expanding access to affordable diagnostics globally. “We expect to deliver double-digit EBITDA growth by 2026 through disciplined execution,” Hedin stated, reaffirming alignment with current financial metrics.

Additional News

Labcorp announced a $450 million CAPEX allocation for digital transformation, emphasizing AI-driven diagnostics and global expansion. The company also highlighted strategic partnerships to strengthen its presence in emerging markets. While no recent M&A activity or C-level changes were disclosed, Labcorp reiterated its commitment to R&D in precision medicine. Additionally, the company aims to maintain affordability in diagnostics globally, aligning with its long-term growth strategy. These initiatives underscore Labcorp’s focus on innovation and market expansion despite near-term operational challenges.

<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-aime_generated_1762014271010.jpg.png" style="max-width:100%;">